Search

Search Constraints

You searched for: Author/Creator Singhal, Shalabh

Search Results

1. 5 Oral selective tyrosine kinase 2 (TYK2) inhibition with BMS-986165 in patients with systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study (PAISLEY). (April 2019)

3. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial. Issue 2 (11th November 2022)

4. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Issue 6 (3rd March 2022)

5. Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects. Issue 4 (19th February 2022)

6. Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants. Issue 1 (8th October 2020)

9. Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting. (4th March 2018)